nach oben

Immunologic Research

Erschienen in:

01.07.2010

Therapeutic HPV DNA vaccines

verfasst von: Ken Lin, Elena Roosinovich, Barbara Ma, Chien-Fu Hung, T.-C. Wu

Erschienen in: Immunologic Research | Ausgabe 1-3/2010

Einloggen, um Zugang zu erhalten

Abstract

It is now well established that most cervical cancers are causally associated with HPV infection. This realization has led to efforts to control HPV-associated malignancy through prevention or treatment of HPV infection. Currently, commercially available HPV vaccines are not designed to control established HPV infection and associated premalignant and malignant lesions. To treat and eradicate pre-existing HPV infections and associated lesions which remain prevalent in the U.S. and worldwide, effective therapeutic HPV vaccines are needed. DNA vaccination has emerged as a particularly promising form of therapeutic HPV vaccines due to its safety, stability and ability to induce antigen-specific immunity. This review focuses on improving the potency of therapeutic HPV vaccines through modification of dendritic cells (DCs) by [1] increasing the number of antigen-expressing/antigen-loaded DCs, [2] improving HPV antigen expression, processing and presentation in DCs, and [3] enhancing DC and T cell interaction. Continued improvement in therapeutic HPV DNA vaccines may ultimately lead to an effective DNA vaccine for the treatment of HPV-associated malignancies.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMed

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMed

Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–32.PubMed

de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17–27.PubMed

Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002;2:59–65.PubMed

zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50.PubMed

Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer. 2006;6:753–63.PubMed

Roden RB, Monie A, Wu TC. Opportunities to improve the prevention and treatment of cervical cancer. Curr Mol Med. 2007;7:490–503.PubMed

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.

10.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43.PubMed

11.

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55.PubMed

12.

Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–8.PubMed

13.

Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24:5571–83.PubMed

14.

Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26(Suppl 10):K53–61.PubMed

15.

Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8:421–39.PubMed

16.

Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA. 1998;95:1800–5.PubMed

17.

Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology. 1998;240:147–57.PubMed

18.

Schafer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer. 1999;81:881–8.PubMed

19.

Fausch SC, Da Silva DM, Eiben GL, Le Poole IC, Kast WM. HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci. 2003;8:s81–91.PubMed

20.

Gerard CM, Baudson N, Kraemer K, Bruck C, Garcon N, Paterson Y, et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine. 2001;19:2583–9.PubMed

21.

Lin CW, Lee JY, Tsao YP, Shen CP, Lai HC, Chen SL. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress. Int J Cancer. 2002;102:629–37.PubMed

22.

Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumours immortalized by HPV-16. J Immunol. 2001;167:6471–9.PubMed

23.

Jabbar IA, Fernando GJ, Saunders N, Aldovini A, Young R, Malcolm K, et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine. 2000;18:2444–53.PubMed

24.

Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Life Sci. 1997;60:163–72.PubMed

25.

Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol. 2000;18:927–74.PubMed

26.

Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine. 2003;21:4036–42.PubMed

27.

Chen CA, Chang MC, Sun WZ, Chen YL, Chiang YC, Hsieh CY, et al. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects. Gene Ther. 2009;16:776–87.PubMed

28.

Luxembourg A, Evans CF, Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther. 2007;7:1647–64.PubMed

29.

Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, Gudmundsdotter L, et al. Skin electroporation: effects on transgene expression, DNA persistence, local tissue environment. PLoS One. 2009;4:e7226.PubMed

30.

Roos AK, Eriksson F, Walters DC, Pisa P, King AD. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Mol Ther. 2009;17:1637–42.PubMed

31.

Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009;27:5450–9.PubMed

32.

Seo SH, Jin HT, Park SH, Youn JI, Sung YC. Optimal induction of HPV DNA vaccine-induced CD8(+) T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine. 2009;27:5906–12.PubMed

33.

Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell D, Weiner DB. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine. 2008;26:5210–5.PubMed

34.

VGX pharmaceuticals, Inc. Phase I of human papillomavirus (HPV) DNA plasmid (VGX-3100) + Electroporation for CIN 2 or 3 [Clinicaltrials.gov identifier NCT00685412]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov. Accessed 2009 October 13.

35.

Mehier-Humbert S, Guy RH. Physical methods for gene transfer: improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev. 2005;57:733–53.PubMed

36.

Zeira E, Manevitch A, Manevitch Z, Kedar E, Gropp M, Daudi N, et al. Femtosecond laser: a new intradermal DNA delivery method for efficient, long-term gene expression and genetic immunization. Faseb J. 2007;21:3522–33.PubMed

37.

Tsen SW, Wu CY, Meneshian A, Pai SI, Hung CF, Wu TC. Femtosecond laser treatment enhances DNA transfection efficiency in vivo. J Biomed Sci. 2009;16:36.PubMed

38.

Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med. 1998;4:365–8.PubMed

39.

Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res. 2002;8:1028–37.PubMed

40.

Storrie H, Mooney DJ. Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. Adv Drug Deliv Rev. 2006;58:500–14.PubMed

41.

Sheets EE, Urban RG, Crum CP, Hedley ML, Politch JA, Gold MA, et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol. 2003;188:916–26.PubMed

42.

Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2004;103:317–26.PubMed

43.

van den Berg JH, Nujien B, Beijnen JH, Vincent A, van Tinteren H, Kluge J, et al. Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther. 2009;20:181–9.PubMed

44.

Pokorna D, Rubio I, Muller M. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants. Genet Vaccines Ther. 2008;6:4.PubMed

45.

Su X, Kim BS, Kim SR, Hammond PT, Irvine DJ. Layer-by-Layer-assembled multilayer films for transcutaneous drug and vaccine delivery. ACS Nano. 2009 Oct 13.

46.

Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol. 2009;333:369–93.PubMed

47.

Voltan R, Castaldello A, Brocca-Cofano E, De Michele R, Triulzi C, Altavilla G, et al. Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice. Vaccine. 2009;27:4498–507.PubMed

48.

Elliott G, O’Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 1997;88:223–33.PubMed

49.

Phelan A, Elliott G, O’Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol. 1998;16:440–3.PubMed

50.

Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CI, et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther. 1999;6:12–21.PubMed

51.

Wybranietz WA, Gross CD, Phelan A, O’Hare P, Spiegel M, Graepler F, et al. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther. 2001;8:1654–64.PubMed

52.

Lundberg M, Johansson M. Is VP22 nuclear homing an artifact? Nat Biotechnol. 2001;19:713–4.PubMed

53.

Kim TW, Hung CF, Kim JW, Juang J, Chen PJ, He L, et al. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther. 2004;15:167–77.PubMed

54.

Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M, et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol. 2001;166:5733–40.PubMed

55.

Peng S, Trimble C, Ji H, He L, Tsai YC, Macaes B, et al. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci. 2005;12:689–700.PubMed

56.

Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC. Improving DNA vaccine potency by linking Marek’s disease virus type 1 VP22 to an antigen. J Virol. 2002;76:2676–82.PubMed

57.

Zheng CF, Brownlie R, Huang DY, Babiuk LA, den Hurk S. Intercellular trafficking of the major tegument protein VP22 of bovine herpesvirus-1 and its application to improve a DNA vaccine. Arch Virol. 2006;151:985–93.PubMed

58.

Zheng C, Babiuk LA, den Hurk S. Bovine herpesvirus 1 VP22 enhances the efficacy of a DNA vaccine in cattle. J Virol. 2005;79:1948–53.PubMed

59.

Onai N, Obata-Onai A, Schmid MA, Manz MG. Flt3 in regulation of type I interferon-producing cell and dendritic cell development. Ann N Y Acad Sci. 2007;1106:253–61.PubMed

60.

Shurin MR, Pandharipande PP, Zorina TD, Haluszczak C, Subbotin VM, Hunter O, et al. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol. 1997;179:174–84.PubMed

61.

Hung CF, Hsu KF, Cheng WF, Chai CY, He L, Ling M, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res. 2001;61:1080–8.PubMed

62.

Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 2002;295:1852–8.PubMed

63.

Pandya MJ, Bendz H, Manzenrieder F, Noessner E, Kessler H, Buchner J, et al. Interaction of human heat shock protein 70 with tumor-associated peptides. Biol Chem. 2009;390:305–12.PubMed

64.

Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the toll/interleukin-1 receptor signal pathway. J Biol Chem. 2002;277:15107–12.PubMed

65.

Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009;15:361–7.PubMed

66.

Johns Hopkins University. Vaccine therapy with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia [ClinicalTrials.gov identifier NCT00788164]. US Natioanl Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov. Accessed 2009 June 4.

67.

Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, van Rooijen N, et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity. 2006;24:191–201.PubMed

68.

Kang TH, Chung JY, Monie A, Pai SI, Hung CF, Wu TC. Enhancing DNA vaccine potency by co-administration of xenogenic MHC-class-I DNA. Gene Ther. 2009 (in press).

69.

Tseng CW, Hung CF, Alvarez RD, Trimble C, Huh WK, Kim D, et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res. 2008;14:3185–92.PubMed

70.

Tseng CW, Monie A, Wu CY, Huang B, Wang MC, Hung CF, et al. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med. 2008;86:899–908.PubMed

71.

Kang TH, Lee JH, Song CK, Han HD, Shin BC, Pai SI, et al. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res. 2007;67:802–11.PubMed

72.

Chuang CM, Monie A, Wu A, Hung CF. Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci. 2009;16:49.PubMed

73.

Tseng CW, Monie A, Trimble C, Alvarez RD, Huh WK, Buchsbaum DJ, et al. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine. 2008;26:4314–9.PubMed

74.

Tseng CW, Trimble C, Zeng Q, Monie A, Alvarez RD, Huh WK, et al. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother. 2009;58:737–48.PubMed

75.

Stacey SN, Jordan D, Williamson AJ, Brown M, Coote JH, Arrand JR. Leaky scanning is the predominant mechanism for translation of human papillomavirus type 16 E7 oncoprotein from E6/E7 bicistronic mRNA. J Virol. 2000;74:7284–97.PubMed

76.

Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC, et al. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci. 2006;13:481–8.PubMed

77.

Cid-Arregui A, Juarez V, zur Hausen H. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol. 2003;77:4928–37.PubMed

78.

Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, et al. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine. 2009;27:431–40.PubMed

79.

Hirasawa Y, Arai M, Imazeki F, Tada M, Mikata R, Fukai K, et al. Methylation status of genes upregulated by demethylating agent 5-aza-2′-deoxycytidine in hepatocellular carcinoma. Oncology. 2006;71:77–85.PubMed

80.

Arai M, Imazeki F, Sakai Y, Mikata R, Tada M, Seki N, et al. Analysis of the methylation status of genes up-regulated by the demethylating agent, 5-aza-2′-deoxycytidine, in esophageal squamous cell carcinoma. Oncol Rep. 2008;20:405–12.PubMed

81.

Lu D, Hoory T, Monie A, Wu A, Wang MC, Hung CF. Treatment with demethylating agent, 5-aza-2′-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine. 2009;27:4363–9.PubMed

82.

Kim D, Hoory T, Monie A, Ting JP, Hung CF, Wu TC. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol. 2008;180:7019–27.PubMed

83.

Grant EP, Michalek MT, Goldberg AL, Rock KL. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J Immunol. 1995;155:3750–8.PubMed

84.

Massa S, Simeone P, Muller A, Benvenuto E, Venuti A, Franconi R. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther. 2008;19:354–64.PubMed

85.

Hung CF, Cheng WF, He L, Ling M, Juang J, Lin CT, et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res. 2003;63:2393–8.PubMed

86.

Smahel M, Polakova I, Pokorna D, Ludvikova V, Duskova M, Vlasak J. Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein. Int J Oncol. 2008;33:93–101.PubMed

87.

Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108:669–78.PubMed

88.

Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. 2004;11:1011–8.PubMed

89.

Kim D, Gambhira R, Karanam B, Monie A, Hung CF, Roden R, et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine. 2008;26:351–60.PubMed

90.

Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 2001;61:3698–703.PubMed

91.

Lin CT, Chang TC, Shaw SW, Cheng PJ, Huang CT, Chao A, et al. Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity. Vaccine. 2006;24:6199–207.PubMed

92.

Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. 2006;24:519–40.PubMed

93.

Wu TC, Guarnieri FG, Staveley-O’Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA. 1995;92:11671–5.PubMed

94.

Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY, et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther. 1999;10:2727–40.PubMed

95.

Huang CH, Peng S, He L, Tsai YC, Boyd DA, Hansen TH, et al. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther. 2005;12:1180–6.PubMed

96.

Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest. 2003;112:109–17.PubMed

97.

Cheng WF, Chang MC, Sun WZ, Lee CN, Lin HW, Su YN, et al. Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. Gene Ther. 2008;15:1007–16.PubMed

98.

Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF, et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 2005;65:309–16.PubMed

99.

Huang B, Mao CP, Peng S, Hung CF, Wu TC. RNA interference-mediated in vivo silencing of Fas ligand as a strategy for the enhancement of DNA vaccine potency. Hum Gene Ther. 2008;19:763–73.PubMed

100.

Hung CF, Tsai YC, He L, Wu TC. DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther. 2007;15:1211–9.PubMed

101.

Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol. 1994;12:259–93.PubMed

102.

Kim D, Monie A, He L, Tsai YC, Hung CF, Wu TC. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses. Gene Ther. 2008;15:677–87.PubMed

103.

Kim D, Hoory T, Wu TC, Hung CF. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell. Hum Gene Ther. 2007;18:1129–39.PubMed

104.

Kim D, Monie A, Tsai YC, He L, Wang MC, Hung CF, et al. Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice. Gene Ther. 2008;15:1176–83.PubMed

105.

Ohlschlager P, Quetting M, Alvarez G, Durst M, Gissmann L, Kaufmann AM. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. Int J Cancer. 2009;125:189–98.PubMed

106.

Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511.PubMed

107.

Larange A, Antonios D, Pallardy M, Kerdine-Romer S. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J Leukoc Biol. 2009;85:673–83.PubMed

108.

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740–5.PubMed

109.

Kojima Y, Xin KQ, Ooki T, Hamajima K, Oikawa T, Shinoda K, et al. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine. 2002;20:2857–65.PubMed

110.

Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol. 2002;2:410–6.PubMed

111.

Song XT, Evel-Kabler K, Rollins L, Aldrich M, Gao F, Huang XF, et al. An alternative, effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med. 2006;3:e11.PubMed

112.

Petrausch U, Poehlein CH, Jensen SM, Twitty C, Thompson JA, Assmann I, et al. Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med. 2009;9:673–82.PubMed

113.

Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007;67:354–61.PubMed

114.

Molling JW, de Gruijl TD, Glim J, Moreno M, Rozendaal L, Meijer CJ, et al. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer. 2007;121:1749–55.PubMed

115.

Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804–11.PubMed

116.

Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E. Vaccination against the fork head family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 2007;67:371–80.PubMed

117.

Chuang CM, Hoory T, Monie A, Wu A, Wang MC, Hung CF. Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+ CD25+ T regulatory cells. Vaccine. 2009;27:684–9.PubMed

118.

Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 2000;60:1035–42.PubMed

119.

Wlazlo AP, Deng H, Giles-Davis W, Ertl HC. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther. 2004;11:457–64.PubMed

120.

Rittich S, Duskova M, Mackova J, Pokorna D, Jinoch P, Smahel M. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2. Oncol Rep. 2005;13:311–7.PubMed

121.

Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81.PubMed

Titel: Therapeutic HPV DNA vaccines
verfasst von: Ken Lin
Elena Roosinovich
Barbara Ma
Chien-Fu Hung
T.-C. Wu
Publikationsdatum: 01.07.2010
Verlag: Humana Press Inc
Erschienen in: Immunologic Research / Ausgabe 1-3/2010
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-009-8141-6

Neu im Fachgebiet HNO

15.04.2024 | Hörsturz | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Therapeutic HPV DNA vaccines

Abstract

Neu im Fachgebiet HNO

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Hundehalter mit Luftnot: War es die Katzenminze?

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-3/2010

Immune regulation in the retina

Immune evasive mechanisms contributing to persistent Leishmania donovani infection

The prevalence of 30 ICD-10 autoimmune diseases in Denmark

IgE antibody-specific activity in human allergic disease

Immunologic research in kidney ischemia/reperfusion injury at Johns Hopkins University

America’s first department of immunology: an informal history

Neu im Fachgebiet HNO

Bilateraler Hörsturz hat eine schlechte Prognose

RRP: Adjuvante HPV-Impfung in jedem Alter empfehlenswert

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Hundehalter mit Luftnot: War es die Katzenminze?

Update HNO